0JQ2 Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
KALA BIO, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.60 |
| 52 Week High | US$11.01 |
| 52 Week Low | US$3.02 |
| Beta | -1.92 |
| 1 Month Change | -4.00% |
| 3 Month Change | -65.75% |
| 1 Year Change | -47.06% |
| 3 Year Change | -89.14% |
| 5 Year Change | -99.38% |
| Change since IPO | -99.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JQ2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.7% | 2.1% | 0.3% |
| 1Y | -47.1% | -13.2% | 0.1% |
Return vs Industry: 0JQ2 underperformed the UK Biotechs industry which returned -13.2% over the past year.
Return vs Market: 0JQ2 underperformed the UK Market which returned -0.4% over the past year.
Price Volatility
| 0JQ2 volatility | |
|---|---|
| 0JQ2 Average Weekly Movement | 20.9% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0JQ2's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0JQ2's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 38 | Todd Bazemore | www.kalarx.com |
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases.
KALA BIO, Inc. Fundamentals Summary
| 0JQ2 fundamental statistics | |
|---|---|
| Market cap | US$22.07m |
| Earnings (TTM) | -US$38.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 0JQ2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JQ2 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.51m |
| Earnings | -US$38.51m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 246.8% |
How did 0JQ2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 16:03 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KALA BIO, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Yi Chen | H.C. Wainwright & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |